[209] Attorney Docket No.: ALX-152.1 CIP

 $\mathbf{S}$  IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

plicant

Evans et al.

Appl. No.

08/487,283

Filed

June 7, 1995

For

METHODS AND COMPOSITIONS FOR THE

TREATMENT OF INFLAMMATORY DISEASES

Examiner

P. Gambel

Group

**1644** 

Commissioner of Patents and Trademarks Washington, D.C. 20231

## **AMENDMENT**

In response to the Office Action dated November 13, 2000, please amend the above-identified application as follows:

## IN THE TITLE:

Please change the title of this application to:

ANTIBODIES TO HUMAN COMPLEMENT COMPONENT C5--

## IN THE ABSTRACT:

Please amend the abstract for this application to read as follows:

The use of anti-C5 antibodies, e.g., monoclonal antibodies, to treat glomerulonephritis (GN) is disclosed. The administration of such antibodies at low dosage levels has been found to significantly reduce glomerular inflammation/enlargement and other pathologic conditions associated with GN. Also disclosed are anti-C5 antibodies and anti-C5 antibody-encoding nucleic acid molecules. These antibodies are useful in the treatment of GN and other inflammatory conditions involving pathologic activation of the complement system.

A copy of the original version of this abstract annotated to show the changes made by this amendment is attached as Exhibit A.

 $\mu$ 

 $W_{i}$ 

 $\langle \mathcal{N} \rangle$